Dipeptidylpeptidase-4 (DPP-4) inhibitors (Formulary)

For use in type 2 diabetes, refer to: Achieving Control in Type 2 diabetes

ALOGLIPTIN - (First line)

Important: Therapy notes

Important: Formulation and dosage details

Formulation:

Tablets 6·25mg, 12·5mg, 25mg

LINAGLIPTIN

Important: Therapy notes

First-line DPP-4 inhibitor of choice in any degree of renal impairment.

Important: Formulation and dosage details

Formulation:

Tablets 5mg

Editorial Information

Document Id: F174